Pattern of Care and Pattern of Survival Study in ca Cervix: Implications of a Published Study
Abstract
This article is being written in the context of the recently published multi-institutional study of POSCC for patients of cervical cancer in India. This study involves both private and public funded institutions and has hospitals from most parts of the country. This study is of utmost relevance in current day India, since India alone accounts for one-fourth of the total burden of disease. Stage I cervical cancer has a fairly good five-year survival of around 80–95 % no matter the mode of treatment chosen. At the other end of the spectrum, 4b has very poor survival rates. The stages in between, II to IVA constitute the major bulk of cancer burden, and are most susceptible to change from treatment variation. As far as the practicing oncologist is concerned, it is knowledge of treatment effects in these patients that make significant difference in overall survival of cervical cancer patients. In this study, over the period of three years, 30% patients in the locally advanced group failed to receive optimal RT. However, no difference in FCS (five year cumulative survival) was observed based purely on optimal dosing of RT. Instead, the study made the observation that the addition of cisplatin to RT (irrespective of the dose of RT) in an optimal dosing (150–200 mg total) was a significant game changer for survival. These conclusions on CT and RT are of utmost significance in suburban and rural India, where patients have to travel long distances to receive RT doses and RT delivery systems are restricted.
Keywords: Concurrent chemo-RT, Ca cervix in India, optimal RT
Cite this Article
Vijaykumar DK, Shruthi Shivdas. Pattern of care and pattern of survival study in ca cervix: implications of a published study. Research and Reviews: Journal of Oncology and Hematology. 2015; 4(3): 14–18p.
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is notpublished already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
_______________
We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |